Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 8.1
edited by Sarantis Dimitriadis
on 2023/05/30 10:01
Change comment: There is no comment for this version
To version 5.9
edited by Sarantis Dimitriadis
on 2022/06/07 08:54
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -7,8 +7,6 @@
7 7  (% class="western" lang="en-GB" style="text-align:justify" %)
8 8  (% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following:
9 9  
10 -:
11 -
12 12  * (((
13 13  (% lang="en-US" %)**Non-professional end users:**
14 14  
... ... @@ -17,8 +17,6 @@
17 17  * (% lang="en-US" %)**Public health and social service clients: **Those who use public services.
18 18  )))
19 19  
20 -:
21 -
22 22  * (((
23 23  (% lang="en-US" %)**Professional end users**
24 24  
... ... @@ -29,13 +29,9 @@
29 29  * (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level.
30 30  )))
31 31  
32 -:
33 -
34 34  (% class="western" lang="en-GB" %)
35 35  (% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows:
36 36  
37 -:
38 -
39 39  * (((
40 40  (% lang="en-US" %)**Private sector organizations: **(business developers and researchers)
41 41  
... ... @@ -50,8 +50,6 @@
50 50  * (% lang="en-US" %)Pharmaceutical companies
51 51  )))
52 52  
53 -:
54 -
55 55  * (((
56 56  (% lang="en-GB" %)
57 57  (% lang="en-US" %)**Public sector organizations:**
... ... @@ -67,8 +67,6 @@
67 67  * (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process.
68 68  )))
69 69  
70 -:
71 -
72 72  * (((
73 73  (% lang="en-GB" %)
74 74  (% lang="en-US" %)**Education and research organizations:**
... ... @@ -82,8 +82,6 @@
82 82  * (% lang="en-US" %)**Private research organizations** such as technology and innovation centers
83 83  )))
84 84  
85 -:
86 -
87 87  * (((
88 88  (% lang="en-GB" %)
89 89  (% lang="en-US" %)**Civil society organizations:**
... ... @@ -91,8 +91,6 @@
91 91  * (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level.
92 92  )))
93 93  
94 -:
95 -
96 96  * (((
97 97  (% lang="en-GB" %)
98 98  (% lang="en-US" %)**Networks and clusters:**
... ... @@ -104,15 +104,18 @@
104 104  :
105 105  
106 106  (% class="western" lang="en-GB" %)
107 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in the following table .
91 +(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table .
108 108  
109 -(% style="height:1004px; margin-left:auto; margin-right:auto; width:1694px" %)
110 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)**Age groups**
111 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
93 +(% style="margin-left:auto; margin-right:auto" %)
94 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)(((
95 +(% class="western" lang="en-GB" style="text-align:center" %)
96 +(% lang="en-US" %)**Age or age group**
97 +)))
98 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
112 112  (% lang="en-US" %)Specific age range
113 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
100 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
114 114  
115 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
102 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
116 116  (% class="western" %)
117 117  
118 118  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
... ... @@ -119,49 +119,147 @@
119 119  (% class="western" %)
120 120  
121 121  )))
122 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Adolescents|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Older Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)General Population
109 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
110 +(% class="western" lang="en-GB" %)
111 +(% lang="en-US" %)Elderly
112 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
113 +(% class="western" lang="en-GB" %)
114 +(% lang="en-US" %)Adults
115 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
116 +(% class="western" lang="en-GB" %)
117 +(% lang="en-US" %)Youth
118 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
119 +(% class="western" lang="en-GB" %)
120 +(% lang="en-US" %)Children
121 +)))
123 123  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
124 124  (% class="western" %)
125 125  
126 126  )))
127 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adolescents Health status (disease, disorder or disability)**
128 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
126 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
127 +(% class="western" lang="en-GB" style="text-align:center" %)
128 +(% lang="en-US" %)**Health status**
129 +)))
130 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
129 129  (% class="western" lang="en-GB" %)
130 130  (% lang="en-US" %)Healthy
131 131  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
132 132  (% class="western" lang="en-GB" %)
133 -
135 +(% lang="en-US" %)Patient
134 134  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
135 135  (% class="western" lang="en-GB" %)
136 -
138 +(% lang="en-US" %)Rehabilitant
137 137  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
138 138  (% class="western" lang="en-GB" %)
139 -
141 +(% lang="en-US" %)Recovered/Survivor
140 140  )))
141 141  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
142 142  (% class="western" %)
143 143  
144 144  )))
145 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adults Health status (disease, disorder or disability)**
146 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Schizophrenia|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Multiple-Sclerosis|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Parkinson Disease
147 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Post-Stroke Patients with Moving or Linguistic Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Mild Cognitive Impairment|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Sleep Disorders: e.g., Apnea, Hypopnea|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)With Disability
148 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy with Possible Chronic Conditions|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %) |(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %) |(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)
147 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
148 +(% class="western" lang="en-GB" style="text-align:center" %)
149 +(% lang="en-US" %)**A specific disease, disorder or disability**
150 +)))
151 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
152 +(% class="western" lang="en-GB" %)
153 +(% lang="en-US" %)ADHD
154 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
155 +(% class="western" lang="en-GB" %)
156 +(% lang="en-US" %)Dementia
157 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
158 +(% class="western" lang="en-GB" %)
159 +(% lang="en-US" %)Parkinsons’ disease
160 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
161 +(% class="western" lang="en-GB" %)
162 +(% lang="en-US" %)Loneliness and Social Isolation
163 +)))
164 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
165 +(% class="western" lang="en-GB" %)
166 +(% lang="en-US" %)Autism
167 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
168 +(% class="western" lang="en-GB" %)
169 +(% lang="en-US" %)Down syndrome
170 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
171 +(% class="western" lang="en-GB" %)
172 +(% lang="en-US" %)Physical disability
173 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
174 +(% class="western" lang="en-GB" %)
175 +(% lang="en-US" %)Mental health
176 +)))
177 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
178 +(% class="western" lang="en-GB" %)
179 +(% lang="en-US" %)Cardiovascular disease
180 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
181 +(% class="western" lang="en-GB" %)
182 +(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF)
183 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
184 +(% class="western" lang="en-GB" %)
185 +(% lang="en-US" %)Sleep apnea/apnea
186 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
187 +(% class="western" lang="en-GB" %)
188 +(% lang="en-US" %)Mild cognitive impairment
189 +)))
190 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
191 +(% class="western" lang="en-GB" %)
192 +(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD)
193 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
194 +(% class="western" lang="en-GB" %)
195 +(% lang="en-US" %)Language disability
196 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
197 +(% class="western" lang="en-GB" %)
198 +(% lang="en-US" %)Substance abuse (drugs, alcohol)
199 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
200 +(% class="western" lang="en-GB" %)
201 +(% lang="en-US" %)Multiple sclerosis
202 +)))
203 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
204 +(% class="western" lang="en-GB" %)
205 +(% lang="en-US" %)Cognitive disorder (mild, major)
206 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
207 +(% class="western" lang="en-GB" %)
208 +(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation
209 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
210 +(% class="western" lang="en-GB" %)
211 +(% lang="en-US" %)Trauma patient
212 +
213 +(% class="western" lang="en-GB" %)
214 +(% lang="en-US" %)(e.g., a spinal cord injury)
215 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
216 +(% class="western" lang="en-GB" %)
217 +(% lang="en-US" %)Neurodegenerative diseases
218 +)))
149 149  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
150 150  (% class="western" %)
151 151  
152 152  )))
153 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Older Adults Health status (disease, disorder or disability)**
154 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy|(% style="border-color:currentcolor; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Parkinson Disease|(% style="border-color:currentcolor; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Mild Cognitive Impairment|(% style="border-color:currentcolor; height:30px; text-align:justify; vertical-align:middle; width:152px" %)With Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
223 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
224 +(% class="western" lang="en-GB" style="text-align:center" %)
225 +(% lang="en-US" %)**Clients of a specific service**
226 +)))
227 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
228 +(% class="western" lang="en-GB" %)
229 +(% lang="en-US" %)Child welfare
230 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
231 +(% class="western" lang="en-GB" %)
232 +(% lang="en-US" %)Nursing home
233 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
234 +(% class="western" lang="en-GB" %)
235 +(% lang="en-US" %)Employment service
236 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
155 155  (% class="western" %)
156 156  
157 157  )))
158 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy with Possible Chronic Conditions|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
240 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
159 159  (% class="western" lang="en-GB" %)
160 -
161 -)))|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
242 +(% lang="en-US" %)Early childhood education
243 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
162 162  (% class="western" lang="en-GB" %)
245 +(% lang="en-US" %)Home care
246 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
247 +(% class="western" lang="en-GB" %)
163 163  
164 -)))|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)(((
249 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
165 165  (% class="western" lang="en-GB" %)
166 166  
167 167  )))
... ... @@ -169,20 +169,70 @@
169 169  (% class="western" %)
170 170  
171 171  )))
172 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**General Population Health status (disease, disorder or disability)**
173 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy|(% style="text-align:justify; vertical-align:middle" %)Ipf Patients|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Prostate Cancer|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
257 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
258 +(% class="western" lang="en-GB" style="text-align:center" %)
259 +(% lang="en-US" %)**Vulnerable groups**
260 +)))
261 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
174 174  (% class="western" lang="en-GB" %)
175 -Down Syndrome
263 +(% lang="en-US" %)Minors/Children
264 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
265 +(% class="western" lang="en-GB" %)
266 +(% lang="en-US" %)Single parents with minor children
267 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
268 +(% class="western" lang="en-GB" %)
269 +(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence
270 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
271 +(% class="western" lang="en-GB" %)
272 +(% lang="en-US" %)Substance users
273 +
274 +(% class="western" lang="en-GB" %)
275 +(% lang="en-US" %)(drugs, alcohol)
176 176  )))
177 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Chronical Diseases: e.g., Persons With Chronic Pulmonary (Copd)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Cardiological Or Other Conditions (Aphasia)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Breast Cancer Survivors|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
277 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
178 178  (% class="western" lang="en-GB" %)
279 +(% lang="en-US" %)Disabled people
280 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
281 +(% class="western" lang="en-GB" %)
282 +(% lang="en-US" %)Victims of trafficking in human beings
283 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
284 +(% class="western" lang="en-GB" %)
285 +(% lang="en-US" %)Ethnic minorities and immigrants
286 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
287 +(% class="western" lang="en-GB" %)
288 +(% lang="en-US" %)Isolated people
289 +)))
290 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
291 +(% class="western" lang="en-GB" %)
292 +(% lang="en-US" %)Elderly people
293 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
294 +(% class="western" lang="en-GB" %)
295 +(% lang="en-US" %)Persons with serious illnesses
296 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
297 +(% class="western" lang="en-GB" %)
298 +(% lang="en-US" %)Homeless people
299 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
300 +(% class="western" lang="en-GB" %)
301 +(% lang="en-US" %)Ex-prisoners and people with criminal background
302 +)))
303 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; text-align:left; vertical-align:middle; width:153px" %)(((
304 +(% class="western" lang="en-GB" %)
305 +(% lang="en-US" %)Pregnant women
306 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
307 +(% class="western" lang="en-GB" %)
308 +(% lang="en-US" %)Persons with mental disorders
309 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
310 +(% class="western" lang="en-GB" %)
179 179  
312 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
313 +(% class="western" lang="en-GB" %)
314 +
180 180  )))
181 181  
182 182  :
183 183  
184 184  (% class="western" lang="en-GB" %)
185 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in (%%)the table below(% style="page-break-before:always" %) .
320 +(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .
186 186  
187 187  |**Researcher expertise**|**Brief use case description**
188 188  |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101007990

Copyright © 2021 VITALISE Project